Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 24Genitourinary 7Thoracic 6Tumor-Agnostic 5Gastrointestinal 5Sarcoma 3Head & Neck 3CNS 3Lymphoid 2Gynecologic 1Endocrine 1Dermatologic 1

Conditions

Neoplasm Metastasis 4Neoplasms 2Adenocarcinoma 1

Interventions

Paclitaxel 27Carboplatin 25pembrolizumab 22Gemcitabine 22Nivolumab 21Cisplatin 15Docetaxel 14Bevacizumab 14Pemetrexed 12Ipilimumab 12Erlotinib Hydrochloride 12Capecitabine 12Irinotecan 11Fluorouracil 11Afatinib 10eribulin 9BI 6727 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9Radiotherapy 8Magnetic Resonance Spectroscopy 8Leucovorin 8Everolimus 8Cyclophosphamide 8olaparib 7Oxaliplatin 7lenvatinib 6avelumab 6Trastuzumab 6Cetuximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × abemaciclib × Tumor-Agnostic × Clear all
NCT04534283 2024-08-07

A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

Indiana University

Phase 2 Terminated
16 enrolled 11 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT03997448 2024-02-20

Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149

Big Ten Cancer Research Consortium

Phase 2 Terminated
3 enrolled 10 charts
Tumor-Agnostic

Adenocarcinoma

NCT02688088 2022-10-18

A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body

Eli Lilly and Company

Phase 1 Completed
48 enrolled 30 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT02919696 2020-09-25

A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic Cancers

Eli Lilly and Company

Phase 1 Completed
26 enrolled 16 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT02117648 2019-01-07

A Study of LY2835219 in Participants With Cancer

Eli Lilly and Company

Phase 1 Completed
26 enrolled 11 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡